MetaCap

Janux Therapeutics (JANX) vs Olema Oncology (OLMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Janux Therapeutics (JANX) has outperformed Olema Oncology (OLMA) over the past year, losing 65.0% versus a loss of 69.7%. Over five years, JANX leads with a -42.9% price change compared with -66.4% for OLMA. Janux Therapeutics is the larger company by market cap ($616.7 million vs $615.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JANX-65.00%OLMA-69.70%
+61%-9%-79%
Nov 21, 20251 yearNov 20, 2026
JANX-43.62%OLMA-69.16%
+281%+86%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JANX versus OLMA key metrics
MetricJANXOLMA
Share price$10.08$7.02
Market cap$616.73M$615.00M
1-day change-2.04%-1.82%
YTD return-26.96%-71.92%
1-year return-65.00%-69.70%
5-year return-42.92%-66.36%
EPS (TTM)$-1.59$-2.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.00M—
Revenue growth (YoY)-5.55%—
Net income (latest FY)$-113.63M$-162.45M
Operating margin-1576.67%—
Net margin-1136.25%—
52-week high$35.34$36.26
52-week low$10.05$6.24
Distance from 52-week high-71.48%-80.64%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+228.77%+405.70%
Average volume961.56K1.27M
Shares outstanding61.18M87.61M
Employees114131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

About Olema Oncology

OLMA stock →

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

JANX vs OLMA FAQ

Which is bigger, Janux Therapeutics or Olema Oncology?

Janux Therapeutics (JANX) is larger, with a market capitalization of $616.73M compared with $615.00M for Olema Oncology (OLMA).

Which stock has performed better over the past year, JANX or OLMA?

JANX returned -65.00% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.

Are Janux Therapeutics and Olema Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons